Current price is more than the intrinsic value

Intrinsic Value

Stock has been generating better return on equity than bank FD

Returns vs FD rates

Stock doesn't offer attractive dividend returns

Dividend Returns

Good time to consider, as stock is not in overbought zone

Entry Point

Stock not in ASM/GSM lists and not a lot of promoter holding is pledged

No Red Flags

Heritage Foods Ltd, Narayana Hrudayalaya Ltd, Vakrangee Ltd and IndusInd Bank Ltd are among the other losers in the BSE’s ‘A’ group today, 23 November 2021.

Syngene International Ltd leads losers in ‘A’ group

#CNBCAwaaz #AajKaTajaKhabar #BusinessNews #StockMarket #ShareMarket #Syngene 

Trading Week के पहले दिन, ताज़ा हालात को देखते हुए, SRF में निवेश पर क्या कहना है Syngene का. क्या आपको Syngene में निवेश करना चाहिए ? अगर आपने पहले से ही Syngene में निवेश कर रखा है तो क्या आपको Position Hold रखनी चाहिए या Stocks बेच देना चाहिए , साथ ही जानें Stoploss और Target.


Share Market से जुडी हर खबर सबसे पहले, CNBC Awaaz पर मिलेगा आपको बढ़िया कमाई का मौका.  यहाँ दिग्गजों के साथ करें कमाई और घर बैठे पाएं Best Trading Ideas के साथ-साथ बिसनेस की दुनिया से जुडी सारी अहम खबरें. 


Share Market से जुड़ी हर छोटी या बड़ी खबर, चाहे हो Nifty में आए नए हाई या फिर, हो आपके के लिए स्टॉक्स पर राय, बिजनेस न्यूज हो या पॉलिटिकल न्यूज, कोरोनावायरस की न्यूज हो या फिर इलेक्शन, देखें CNBC Awaaz और रहे हर खबर से updated.


CNBC Awaaz is India’s number one business channel and an undisputed leader in business news and information for the last ten years. Our channel aims to educate, inform and inspire consumers to go beyond limitations, with practical tips on personal finance, investing, technology, consumer goods and capital markets. Policymakers and business owners alike have grown to trust CNBC Awaaz as the most reliable source with its eye on India’s business climate. Our programming gives consumers a platform to make decisions with confidence.

Subscribe to the CNBC Awaaz YouTube channel here: https://tinyurl.com/y5rsvesk

Follow CNBC Awaaz on Twitter: https://twitter.com/CNBC_Awaaz
Like us on our CNBC Awaaz Facebook page: https://www.facebook.com/cnbcawaaz

Syngene में निवेश करें या नहीं, Expert से जानें | Pehla Sauda | CNBC Awaaz

Here’s what Mazhar Mohammad of chartviewindia.in, recommends investors should do with these stocks when the market resumes trading today.

Trade Spotlight | What Should You Do With Apollo Hospitals, Syngene International, Metropolis & IRCTC Stocks?

For India Inc, with a traditionally poor record of hiring expat CEOs, the stints of people like Paris-based Frenchman Thierry Delaporte (Wipro), Israeli national Erez Israeli (Dr Reddys Laboratories), British national Jonathan Hunt (Syngene, Biocon), American Brian Bade (Reliance Retail Digital) and…

View: Corporate culture, world is a CEO oyster for India Inc

Engineers India, Star Cement and Syngene International too can decline up to 7% in the medium term, indicate charts

HDFC Life, IndiaMART: These 5 stocks can fall up to 10%. Should you sell?

Key client markets in the US and Europe that are in process of returning to normal operations are helping the company’s discovery services segment

Syngene sees medium-term growth prospects intact despite some margin pressure

In an interview to ET, Jonathan Hunt, CEO and MD of Syngene said the company has spare capacity and is also investing on expansion of microbial and mammalian manufacturing capacities to absorb the pent up demand for biological manufacturing.

Seeing good demand for biologics manufacturing: Syngene CEO Jonathan Hunt

ICICI Direct is bullish on Syngene International has recommended buy rating on the stock with a target price of Rs 710 in its research report dated October 22, 2021.

Buy Syngene International; Target Of Rs 710: ICICI Direct

Syngene continues to guide for a mid-teen revenue growth in FY22. This appears possible, given the improved demand scenario and the strong traction in H1 FY22

Syngene: Look Beyond The Near-term Input Cost Pressure

Syngene International Q2 Review - Decent Numbers Despite Some Margin Pressure: ICICI Direct

Syngene International Q2 Review - Higher Inventory Impacts Q2, Long Term Outlook Intact: Dolat Capital

Syngene International Limited is a contract research company. It is engaged in providing contract research and manufacturing services in early-stage drug discovery and development to pharmaceutical and biotechnology companies.

Syngene International Ltd

Syngene International Ltd

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

Returns vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's return on equity is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Syngene International Ltd leads losers in ‘A’ group

News Video

Syngene में निवेश करें या नहीं, Expert से जानें | Pehla Sauda | CNBC Awaaz

Trade Spotlight | What Should You Do With Apollo Hospitals, Syngene International, Metropolis & IRCTC Stocks?

View: Corporate culture, world is a CEO oyster for India Inc

HDFC Life, IndiaMART: These 5 stocks can fall up to 10%. Should you sell?

Syngene sees medium-term growth prospects intact despite some margin pressure

Seeing good demand for biologics manufacturing: Syngene CEO Jonathan Hunt

Syngene International Ltd

Intrinsic ValueIntrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

Returns vs FD ratesFixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's return on equity is lower than this rate, investors are better off investing the amount in a FD

Dividend ReturnsA dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry PointHigh demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Syngene International Ltd leads losers in ‘A’ group

News Video

Syngene में निवेश करें या नहीं, Expert से जानें | Pehla Sauda | CNBC Awaaz

Trade Spotlight | What Should You Do With Apollo Hospitals, Syngene International, Metropolis & IRCTC Stocks?

View: Corporate culture, world is a CEO oyster for India Inc

HDFC Life, IndiaMART: These 5 stocks can fall up to 10%. Should you sell?

Syngene sees medium-term growth prospects intact despite some margin pressure

Seeing good demand for biologics manufacturing: Syngene CEO Jonathan Hunt

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

Returns vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's return on equity is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock